Home | Pharming

Pharming's Technology Platform

Our transgenic platform remains the only technology that to date can deliver recombinant versions of certain complex human proteins in an economically viable way.

Transforming the future for our patients

Press releaseMay 16

Pharming today celebrates “hae day :-)” – the global awareness day for hereditary angioedema, a rare life-threatening condition.

Press releaseMay 16

Pharming Group reports interim financial results for the first quarter of 2019

Press releaseApril 10

Pharming Group announces Notice to Convene to Annual General Meeting of Shareholders

RUCONEST® (conestat alfa)

RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE

Upcoming events

View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page.

View all events

Career opportunities

Our innovative technology and processes are aimed at purification and formulation of recombinant products. We are continuously looking for highly talented and motivated individuals to join our team.

See our open positions here

Cookies: This website uses cookies Check the cookies page for more information Accept Decline